The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Interim results from the Phase II DALY II USA trial: zamto-cel in patients with R/R DLBCL
In this video, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the interim results from a Phase II pivotal study of zamtocabtagene autoleucel (zamto-cel), a tandem CD20xCD19-directed non-cryopreserved CAR T-cell product, in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Shah highlights that the study’s novel manufacturing platform, which delivers fresh CAR T-cells in a rapid timeline, has shown a 73% overall response rate (ORR), 51% complete response (CR) rate, and 55% six-month progression-free survival (PFS) in a challenging patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
